Naratriptan-Hormosan (Naratriptan)

Naratriptan belongs to the Triptan class and is used for the acute management of migraine attacks.

• Migraine (with aura): provides rapid relief of headache pain and associated symptoms.
• Migraine (without aura): reduces the severity and duration of an acute migraine episode.
• Menstrual migraine: offers effective acute treatment for migraine linked to menstrual cycles.

• Naratriptan acts as a selective agonist at serotonin 5‑HT1B and 5‑HT1D receptors located on intracranial blood vessels and trigeminal nerve endings. Activation of these receptors causes cranial vasoconstriction and inhibits the release of pro‑inflammatory neuropeptides, thereby interrupting the pain signaling cascade responsible for migraine.

Common Side Effects

• Nausea: mild to moderate feeling of stomach upset.
• Dizziness: transient light‑headedness or vertigo.
• Fatigue: temporary tiredness or reduced energy.
• Dry mouth: reduced salivation leading to throat discomfort.

Serious or Rare Side Effects

• Chest pain: may indicate cardiac ischemia and requires immediate evaluation.
• Serotonin syndrome: risk when combined with other serotonergic agents, presenting with agitation, hyperthermia, and neuromuscular abnormalities.
• Severe hypertension: sudden rise in blood pressure that can be dangerous.
• Allergic reaction: rash, itching, swelling, or difficulty breathing.
• Myocardial infarction: rare but life‑threatening heart attack.

Before prescribing Naratriptan, clinicians should evaluate cardiovascular health and potential drug interactions.

• Assess cardiovascular risk: avoid use in patients with uncontrolled hypertension or coronary artery disease.
• Avoid use with ergotamine derivatives: combined vasoconstriction may increase vascular complications.
• Caution with serotonergic drugs: monitor for signs of serotonin syndrome.
• Use carefully in hepatic impairment: dose adjustment may be required.
• Store at room temperature: keep in the original pack, protect from moisture.

Naratriptan may interact with several medication classes, requiring careful management.

Major Interactions (Avoid)

• Ergotamine derivatives: additive vasoconstriction can precipitate severe vascular events.
• Monoamine oxidase inhibitors (MAOIs): increase risk of serotonin syndrome.
• SSRIs or SNRIs combined with other serotonergic agents: heightened serotonin toxicity.

Moderate Interactions (Monitor Closely)

• Other triptans: cumulative serotonergic effect may raise adverse event risk.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase naratriptan plasma levels.
• CYP3A4 inducers (e.g., rifampin): may reduce therapeutic effectiveness.